Patents Represented by Attorney Charles W. Ashbrook

Find this attorney in the Justia Lawyer Directory

  • Phosphodiesterase IV-inhibiting diazepinoindoles
    Patent number: 6365585
    Abstract: Metabolites of the products of formula (I) in which A and R are as defined in the description, which are phosphodiesterase 4 inhibitors.
    Type: Grant
    Filed: June 7, 2000
    Date of Patent: April 2, 2002
    Assignee: Warner-Lambert Company
    Inventors: Henry Jacobelli, Christine Julien-Larose, Sylvie Marc
  • Isoquinolones
    Patent number: 6362181
    Abstract: Benzo[de]isoquinoline-1,3-diones which are selective inhibitors of bacterial DNA gyrase and DNA topoisomerase useful in antibacterial agents are described as well as methods for their preparation and formulation. Novel intermediates useful in the preparation of the final products are also described.
    Type: Grant
    Filed: August 11, 2000
    Date of Patent: March 26, 2002
    Assignee: Warner-Lambert Company
    Inventors: Albert Kudzoi Amegadzie, Maureen Elizabeth Carey, John Michael Domagala, Liren Huang, Ronald George Micetich, Joseph Peter Sanchez, Rajeshwar Singh, Michael Andrew Stier, Arkadii Vaisburg
  • Reduced dipeptide analogues as calcium channel antagonitsts
    Patent number: 6362174
    Abstract: The present invention provides novel N-type calcium channel blockers, compositions comprising them, and methods of their use. The compounds of the invention are useful in the treatment of stroke, cerebral ischemia, pain, epilepsy, and head trauma.
    Type: Grant
    Filed: August 9, 2001
    Date of Patent: March 26, 2002
    Assignee: Warner-Lambert Company
    Inventors: Michael Francis Rafferty, Yuntao Song
  • Inhibition of lipoprotein oxidation
    Patent number: 6362236
    Abstract: Hydroxylated derivatives of cholesterol lowering agents inhibit the oxidation of lipoproteins, and are thus useful for preventing the progression of atherogenesis and resultant vascular diseases, including heart attacks.
    Type: Grant
    Filed: February 7, 2000
    Date of Patent: March 26, 2002
    Assignee: Warner-Lambert Company
    Inventors: Michael Aviram, Charles Larry Bisgaier, Roger Schofield Newton, Mira Rosenblat
  • Method for preventing and treating arthritis, osteo-traumatic pain, and neuralgias with trimebutine
    Patent number: 6353024
    Abstract: The invention relates to the use of trimebutine [2-dimethylamino-2-phenylbutyl-3,4,5-trimethoxy-benzoate hydrogen maleate] or its corresponding stereoisomers for the preparation of a medicament to prevent and/or treat arthritis, osteo-traumatic pain, and neuralgias.
    Type: Grant
    Filed: January 24, 2000
    Date of Patent: March 5, 2002
    Assignee: Warner-Lambert Company
    Inventors: Agnès Grouhel, Gilles Brunelle, François Roman, Jacques Hamon
  • Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
    Patent number: 6340709
    Abstract: This invention provides a method for treating and preventing neurological disorder such as Alzheimer's disease, and for promoting wound healing comprising administering a compound characterized as being a matrix metalloproteinase inhibitor.
    Type: Grant
    Filed: March 19, 1999
    Date of Patent: January 22, 2002
    Assignee: Warner-Lambert Company
    Inventors: Thomas Michael Andrew Bocan, Peter Alan Boxer, Joseph Thomas Peterson, Jr., Denis Schrier, Andrew David White
  • Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents
    Patent number: 6340758
    Abstract: Described are neuroprotective agents of Formula I wherein R is an amino acid or nitrogen heterocyclic ring which is saturated or unsaturated of from 5 to 8 members which may have additional oxygen or sulfur atoms therein. The other provisions or substituents are described in the specification.
    Type: Grant
    Filed: November 25, 1998
    Date of Patent: January 22, 2002
    Assignee: Warner-Lambert Company
    Inventors: Brian Edward Kornberg, Sham Shridhar Nikam, Michael Francis Rafferty
  • 7-substituted quinazolin-2,4-diones useful as antibacterial agents
    Patent number: 6331538
    Abstract: The invention is a series of 7-substituted quinazolin-2,4-diones useful as antibacterial agents, processes for the preparation of the compounds, and a pharmaceutical composition containing one or more of the compounds.
    Type: Grant
    Filed: March 15, 2000
    Date of Patent: December 18, 2001
    Assignee: Warner-Lambert Company
    Inventors: John Michael Domagala, Edmund Lee Ellsworth, Liren Huang, Thomas Eric Renau, Rajeshwar Singh, Michael Andrew Stier
  • Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases
    Patent number: 6329429
    Abstract: GABA analogs such as gabapentin and pregabalin are useful to prevent and treat inflammatory diseases.
    Type: Grant
    Filed: October 25, 1999
    Date of Patent: December 11, 2001
    Assignee: Warner-Lambert Company
    Inventors: Denis Schrier, Charles Price Taylor, Jr., Karin Nanette Westlund High
  • Compositions comprising GABA analogs and caffeine
    Patent number: 6326374
    Abstract: Compositions that comprise a GABA analog, such as gabapentin or pregabalin in combination with caffeine are disclosed. The compositions are used to treat pain in mammals.
    Type: Grant
    Filed: January 9, 2001
    Date of Patent: December 4, 2001
    Assignee: Warner-Lambert Company
    Inventors: Leslie Magnus, Catherine A. Segal
  • Tyrosine-derived compounds as calcium channel antagonists
    Patent number: 6323243
    Abstract: The present invention provides compounds that block calcium channels and have the Formula I: and pharmaceutically acceptable salts, esters, and pro-drugs thereof, wherein R1 and R2 are independently H, phenylcyclopentylcarbonyl, C1-C7 alkyl, cyclohexylmethyl, benzyl, C1-C5 alkylbenzyl, or C1-C5 alkoxybenzyl, A is —C(O)— or —CH2—; R3 is H or —CH3; R4 is C1-C4 alkyl or piperidin-1-ylethyl; R5 is phenyl-(CH2)n—, C1-C4 alkylphenyl-(CH2)n—, or halophenyl-(CH2)n—; and n is 1 or 2. The present invention also provides pharmaceutical compositions containing the compounds of Formula I and methods of using them to treat stroke, cerebral ischemia, head trauma, and epilepsy.
    Type: Grant
    Filed: October 24, 2000
    Date of Patent: November 27, 2001
    Assignee: Warner-Lambert Company
    Inventors: Michael Francis Rafferty, Yuntao Song
  • Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel
    Patent number: 6316638
    Abstract: Novel substituted amino acids of formula are disclosed and are useful as agents in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, and neuropathological disorders. Processes for the preparation and intermediates useful in the preparation are also disclosed.
    Type: Grant
    Filed: August 16, 2000
    Date of Patent: November 13, 2001
    Assignee: Warner-Lambert Company
    Inventors: Justin Stephen Bryans, David Christopher Horwell, Jean-Marie Receveur
  • Reduced dipeptide analogues as calcium channel antagonists
    Patent number: 6316440
    Abstract: The present invention provides novel N-type calcium channel blockers, compositions comprising them, and methods of their use. The compounds of the invention are useful in the treatment of stroke, cerebral ischemia, pain, epilepsy, and head trauma.
    Type: Grant
    Filed: December 27, 1999
    Date of Patent: November 13, 2001
    Assignee: Warner-Lambert Company
    Inventors: Michael Francis Rafferty, Yuntao Song
  • 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
    Patent number: 6310060
    Abstract: Phenylamino benzoic acid, benzamides, and benzyl alcohol derivatives of the formula where R1, R2, R3, R4, R5, and R6 are hydrogen or substituent groups such as alkyl, and where R7 is hydrogen or an organic radical, and Z is COOR7, tetrazolyl, CONR6R7, or CH2OR7, are potent inhibitors of MEK and, as such, are effective in treating cancer and other proliferative diseases such as inflammation, psoriasis and restenosis, as well as stroke, heart failure, and immunodeficiency disorders.
    Type: Grant
    Filed: January 5, 2000
    Date of Patent: October 30, 2001
    Assignee: Warner-Lambert Company
    Inventors: Stephen Douglas Barrett, Alexander James Bridges, Donna Reynolds Cody, Annette Marian Doherty, David Thomas Dudley, Alan Robert Saltiel, Mel Conrad Schroeder, Haile Tecle
  • Use of Gaba-analogues for treating insomnia
    Patent number: 6306910
    Abstract: The instant invention is a method of using analogs of glutamic acid and gamma-aminobutyric acid to treat insomnia.
    Type: Grant
    Filed: January 9, 2001
    Date of Patent: October 23, 2001
    Assignee: Warner-Lambert Company
    Inventors: Leslie Magnus, Catherine A. Segal
  • Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase
    Patent number: 6300501
    Abstract: Inhibitors of protein farnesyl transferase enzymes are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating cancer, restenosis, psoriasis, endometriosis, atherosclerosis, or viral infections.
    Type: Grant
    Filed: November 2, 1998
    Date of Patent: October 9, 2001
    Assignee: Warner-Lambert Company
    Inventors: Ellen M. Dobrusin, Annette M. Doherty, James S. Kaltenbronn, Daniele M. Leonard, Dennis J. McNamara, Judith Sebolt-Leopold, Kevon R. Shuler
  • Sulfonamide inhibitors of matrix metalloproteinases
    Patent number: 6297247
    Abstract: Sulfonamide compounds are described which are inhibitors of matrix metalloproteinases, particularly stromelysin-1 and gelatinase A (72 kD gelatinase). Also described are methods for the treatment of multiple sclerosis, atherosclerotic plaque rupture, aortic aneurism, heart failure, restenosis, periodontal disease, corneal ulceration, burns, decubital ulcers, chronic ulcers or wounds, cancer metastasis, tumor angiogenesis, arthritis, or other autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes using the compounds.
    Type: Grant
    Filed: June 22, 2000
    Date of Patent: October 2, 2001
    Assignee: Warner-Lambert Company
    Inventors: Daniel F. Ortwine, Claude F. Purchase, Jr., Andrew D. White
  • Dibenzofuran sulfonamide matrix metalloproteinase inhibitors
    Patent number: 6294674
    Abstract: The present invention relates to compounds of Formula I that inhibit matrix metalloproteinases and to a method of inhibiting matrix metalloproteinases using the compounds. wherein Q is an un-natural amino acid. More particurlarly, the present invention relates to a method of treating diseases in which matrix metalloproteinases are involved such as multiple sclerosis, atherosclerotic plaque rupture, restenosis, aortic aneurism, heart failure, periodontal disease, corneal ulceration, burns, decubital ulcers, chronic ulcers or wounds, cancer metastasis, tumor angiogenesis, arthiritis, or other autoimmune or inflammatory diseases dependent upon tissue invasion by leukocytes.
    Type: Grant
    Filed: March 2, 1999
    Date of Patent: September 25, 2001
    Assignee: Warner-Lambert Company
    Inventors: Joseph Armand Picard, Drago Robert Sliskovic
  • Method for treating diseased-related or drug-induced dyskinesias
    Patent number: 6284776
    Abstract: Dyskinesias in humans are treated by administering a therapeutically effective dose of an NR1A/2B site-selective NMDA receptor antagonist compound to a human suffering therefrom.
    Type: Grant
    Filed: February 7, 2000
    Date of Patent: September 4, 2001
    Inventor: Leonard T. Meltzer
  • Sulfonamide compounds and methods of treating atherosclerosis and restenosis
    Patent number: 6284795
    Abstract: The present invention provides compounds having the Formula I The present invention also provides methods of treating or preventing atherosclerosis, coronary heart disease, and restenosis using the compounds of Formula I, and pharmaceutical compositions comprising the compounds of Formula I.
    Type: Grant
    Filed: August 18, 1999
    Date of Patent: September 4, 2001
    Assignee: Warner-Lambert Company
    Inventors: Helen Tsenwhei Lee, Randy Ranjee Ramharack, Bruce David Roth, Karen Elaine Sexton